CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
1 research outputs found
Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS).
Author
E. Premkumar Reddy
Erin P Demakos
+7Â more
Fumiko Isoda
Jamari Ross
Lewis R. Silverman
Pratima Chaurasia
Rosalie Odchimar-Reissig
Shyamala Chendal Navada
Tylar Novy
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref